Literature DB >> 27400227

Combining Diffusion Tensor Imaging and Susceptibility Weighted Imaging on the Substantia Nigra of 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (MPTP)-induced Rhesus Monkey Model of Parkinson's Disease.

Q Zhang1, L Li2, B Miao3, H Niu4.   

Abstract

Objective: The aim of this study was to evaluate whether combining diffusion tensor magnetic resonance imaging (DTI) and susceptibility weighted imaging (SWI) techniques would provide a sensitive method for differentiating between 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced rhesus monkey model of Parkinson's disease (PD) and wild-type controls. Subjects and
Methods: Seventeen rhesus monkeys were divided into two groups. A series of intramuscular injections of either saline (control group, n = 8) or MPTP (0.2 mg/kg body weight; PD group, n = 9) were given to the monkeys, twice a week. Then, SWI and DTI scans were obtained from the monkeys with Siemens Magnetom Verio 3.0T superconductive MRI system. Region of interest analysis was performed on substantia nigra pars compacta (SNc) and substantia nigra pars reticulata (SNr). In addition, immunohistochemical staining of tyrosine hydroxylase was applied to assess degeneration of SN dopaminergic neurons.
Results: Monkeys in the PD group displayed mild to moderate motor symptoms assessed using Kurlan's scale. With SWI scans, decreased width of SNc but increased width of SNr was found in PD group monkeys compared to controls. Calculation of the ratios of widths of SNc and SNr to the anterior and posterior mesencephalic diameter also reflected narrower SNc but wider SNr than controls. Decreased SWI signal intensity of SNc and SNr suggested iron deposition in both subregions of SN. The DTI scans showed lower fractional anisotropy (FA) values in SNc of the PD group monkeys, while no change of FA values in SNr was detected. Immunohistochemical test displayed generalized loss of dopaminergic neurons in SN of PD group monkeys.
Conclusion: Combining the use of DTI and SWI can provide a sensitive method for differentiating between MPTP-induced rhesus monkey model of PD and wild-type controls. This effective imaging modality might provide additional information for characteristic identification of PD at early stages, thus enhancing the ability to make early diagnosis, and monitor progression of the natural history and treatment effects.

Entities:  

Year:  2016        PMID: 27400227      PMCID: PMC4961335          DOI: 10.7727/wimj.2016.051

Source DB:  PubMed          Journal:  West Indian Med J        ISSN: 0043-3144            Impact factor:   0.171


  26 in total

1.  Diffusion tensor imaging in a rat model of Parkinson's disease after lesioning of the nigrostriatal tract.

Authors:  Nadja Van Camp; Ines Blockx; Marleen Verhoye; Cindy Casteels; Frea Coun; Alexander Leemans; Jan Sijbers; Veerle Baekelandt; Koen Van Laere; Annemie Van der Linden
Journal:  NMR Biomed       Date:  2009-08       Impact factor: 4.044

2.  Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI.

Authors:  P J Basser; C Pierpaoli
Journal:  J Magn Reson B       Date:  1996-06

3.  Relationship between oscillatory activity in the cortico-basal ganglia network and parkinsonism in MPTP-treated monkeys.

Authors:  Annaelle Devergnas; Damien Pittard; Donald Bliwise; Thomas Wichmann
Journal:  Neurobiol Dis       Date:  2014-04-21       Impact factor: 5.996

4.  Connectivity-based segmentation of the substantia nigra in human and its implications in Parkinson's disease.

Authors:  Ricarda A Menke; Saad Jbabdi; Karla L Miller; Paul M Matthews; Mojtaba Zarei
Journal:  Neuroimage       Date:  2010-10-01       Impact factor: 6.556

5.  Diffusion tensor imaging reveals white matter changes associated with cognitive status in patients with Parkinson's disease.

Authors:  Bingmei Deng; Yuhu Zhang; Lijuan Wang; Kairun Peng; Lixin Han; Kun Nie; Hongjun Yang; Li Zhang; Jun Wang
Journal:  Am J Alzheimers Dis Other Demen       Date:  2012-12-26       Impact factor: 2.035

6.  Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

Authors:  Gunasingh J Masilamoni; James W Bogenpohl; David Alagille; Kristen Delevich; Gilles Tamagnan; John R Votaw; Thomas Wichmann; Yoland Smith
Journal:  Brain       Date:  2011-07       Impact factor: 13.501

7.  Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities.

Authors:  Roberta Biundo; Patrizia Formento-Dojot; Silvia Facchini; Annamaria Vallelunga; Luca Ghezzo; Luciano Foscolo; Francesca Meneghello; Angelo Antonini
Journal:  J Neurol Sci       Date:  2011-08-23       Impact factor: 3.181

8.  Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease.

Authors:  Yu Zhang; I-Wei Wu; Shannon Buckley; Christopher S Coffey; Eric Foster; Susan Mendick; John Seibyl; Norbert Schuff
Journal:  Mov Disord       Date:  2015-04-29       Impact factor: 10.338

9.  Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery.

Authors:  Xiangmin Lin; Min Shi; Jeyaraj Gunasingh Masilamoni; Romel Dator; James Movius; Patrick Aro; Yoland Smith; Jing Zhang
Journal:  Biochim Biophys Acta       Date:  2015-01-22

Review 10.  Stem cell-based approach for the treatment of Parkinson's disease.

Authors:  Parisa Goodarzi; Hamid Reza Aghayan; Bagher Larijani; Masoud Soleimani; Ahmad-Reza Dehpour; Mehrnaz Sahebjam; Firoozeh Ghaderi; Babak Arjmand
Journal:  Med J Islam Repub Iran       Date:  2015-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.